Obstructive Sleep Apnea (OSA)
Conditions
Keywords
sleep apnea, intermittent hypoxia, neutrophil extracellular traps, cathelicidins
Brief summary
The study will enroll 80 moderate-to-severe Obstructive sleep apnea (OSA) patients (40 obese) and 40 age-, gender-, and body mass index-matched controls. Venous blood will be collected to isolate neutrophils, which will be tested for the ability to produce neutrophil extracellular traps (NETs) along with the levels of LL-37 and NETs products in the blood. Measurements will be repeat after three months treatment for OSA.
Detailed description
Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse during sleep, thereby leading to intermittent hypoxia (IH). Literature revealed OSA confers a higher risk for poor infection outcomes, suggestive of defective immunity in those patients. This research aimed to investigate whether IH inhibits neutrophils to produce neutrophil extracellular traps (NETs) via Cathelicidins (LL-37). The human study will enroll 80 moderate-to-severe OSA patients (40 obese) and 40 age-, gender-, and body mass index-matched controls. Venous blood will be collected to isolate neutrophils, which receive either IH treatment (1% O2 for 35 mins and 21% for 25 mins per cycle, 3 cycles) or normoxic treatment. The neutrophils will be tested for the ability to produce NETs along with the levels of LL-37 and NETs products in the blood. Measurements will be repeat three months after the mainstay continuous positive airway pressure (CPAP) therapy.
Interventions
DEVICECPAP
Continuous positive airway pressure (CPAP) is the standard treatment for moderate to severe OSA in clinical practice.
Sponsors
National Science and Technology Council, Taiwan
Kun-Ta Chou
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* At least 20 years old, with moderate to severe OSA (AHI ≥ 15/hour), and willing to participate in the study.
Exclusion criteria
* Under 20 years old, suffering from diseases or conditions that may affect immune function (e.g., tumors, chemotherapy, autoimmune diseases, diabetes, chronic kidney disease, etc.), or unwilling to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NET activity of neutrophils induced by PMA | From enrollment to receiving CPAP therapy for 3 months | 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Neutrophils are isolated from peripheral blood and stimulated with PMA (phorbol 12-myristate 13-acetate) to induce the formation of NETs. The effects were tested with or without intermittent hypoxia (IH) treatment (1% O₂ for 35 minutes followed by 21% O₂ for 25 minutes per cycle, repeated for three cycles). The extent of NETs formation was assessed by confocal microscopy and images were exported as multi-channel TIFF files and analyzed using custom Python scripts (NumPy, scikit-image). |
| DNA-MPO (Myeloperoxidase) complex in plasma | From enrollment to receiving CPAP therapy for 3 months | Description: 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Plasma is collected and tested for DNA-MPO (Myeloperoxidase) complex by ELISA (Enzyme-linked immunosorbent assay). |
| LL-37 level in plasma | From enrollment to receiving CPAP therapy for 3 months | 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Plasma is collected and tested for LL-37 by ELISA (Enzyme-linked immunosorbent assay). |
Other
| Measure | Time frame | Description |
|---|---|---|
| LL-37 in the supernatant of cultured neutrophils | From enrollment to receiving CPAP therapy for 3 months | 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Neutrophils are isolated from peripheral blood and stimulated with PMA (phorbol 12-myristate 13-acetate) to induce the formation of NETs. Supernatant of cultured neutrophils are collected and tested for LL-37 by ELISA. |
| MPO (Myeloperoxidase) in the supernatant of cultured neutrophils | From enrollment to receiving CPAP therapy for 3 months | 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Neutrophils are isolated from peripheral blood and stimulated with PMA (phorbol 12-myristate 13-acetate) to induce the formation of NETs. Supernatant of cultured neutrophils are collected and tested for MPO (Myeloperoxidase )by ELISA. |
| NE (Neutrophil elastase) in the supernatant of cultured neutrophils | From enrollment to receiving CPAP therapy for 3 months | 10 cc peripheral venous blood of participants will be collected at enrollment and 3 months after CPAP therapy (if received it). Neutrophils are isolated from peripheral blood and stimulated with PMA (phorbol 12-myristate 13-acetate) to induce the formation of NETs. Supernatant of cultured neutrophils are collected and tested for NE (Neutrophil elastase) by ELISA. |
Countries
Taiwan
Contacts
Primary ContactKun-Ta Chou, M.D & Ph.D
Outcome results
None listed